acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Company profile
Ticker
ACORQ, ACORQ
Exchange
Website
CEO
Ron Cohen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ACORDA THERAPEUTICS INC
SEC CIK
Corporate docs
Subsidiaries
Acorda Therapeutics Limited • Acorda Therapeutics Ireland Limited • Biotie Therapies AG • Biotie Therapies, LLC. • Civitas Therapeutics, Inc. • Neuronex, Inc. ...
ACORQ stock data
Latest filings (excl ownership)
8-K
Acorda Therapeutics Announces Delisting from Nasdaq
17 Apr 24
8-K
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
1 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K
Amendments to Articles of Incorporation or Bylaws
13 Mar 24
8-K
Termination of a Material Definitive Agreement
11 Jan 24
8-K
Other Events
1 Dec 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
8 Aug 23
Transcripts
ACORQ
Earnings call transcript
2023 Q3
13 Nov 23
ACORQ
Earnings call transcript
2023 Q2
8 Aug 23
ACORQ
Earnings call transcript
2023 Q1
11 May 23
ACORQ
Earnings call transcript
2022 Q4
9 Mar 23
ACORQ
Earnings call transcript
2022 Q3
1 Nov 22
ACORQ
Earnings call transcript
2022 Q2
7 Aug 22
ACORQ
Earnings call transcript
2022 Q1
12 May 22
ACORQ
Earnings call transcript
2021 Q4
10 Mar 22
ACORQ
Earnings call transcript
2021 Q3
10 Nov 21
ACORQ
Earnings call transcript
2021 Q2
8 Aug 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 33.58 mm | 33.58 mm | 33.58 mm | 33.58 mm | 33.58 mm | 33.58 mm |
Cash burn (monthly) | (no burn) | 49.92 k | 3.31 mm | 1.55 mm | (no burn) | 158.33 k |
Cash used (since last report) | n/a | 330.62 k | 21.95 mm | 10.25 mm | n/a | 1.05 mm |
Cash remaining | n/a | 33.25 mm | 11.63 mm | 23.33 mm | n/a | 32.54 mm |
Runway (months of cash) | n/a | 666.2 | 3.5 | 15.1 | n/a | 205.5 |
Institutional ownership, Q2 2023
12.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 15 |
Opened positions | 14 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 907.19 mm |
Total shares | 149.36 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Davidson Kempner Capital Management | 55.15 k | $716.89 mm |
Renaissance Technologies | 45.56 k | $593.00 k |
Acadian Asset Management | 34.13 k | $442.00 k |
BLK Blackrock | 6.78 k | $88.16 mm |
WFC Wells Fargo & Co. | 3.74 k | $48.66 mm |
DB Deutsche Bank AG - Registered Shares | 1.70 k | $22.12 mm |
MS Morgan Stanley | 1.28 k | $16.60 mm |
RY Royal Bank Of Canada | 516.00 | $7.00 mm |
Russell Investments | 300.00 | $3.90 mm |
Group One Trading | 204.00 | $2.65 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Jun 23 | Varian John | Non-Employee Stock Option Common Stock | Grant | Acquire A | No | No | 12.99 | 1,200 | 15.59 k | 1,200 |
22 Jun 23 | Kelley John P | Non-Employee Stock Option Common Stock | Grant | Acquire A | No | No | 12.99 | 1,200 | 15.59 k | 1,200 |
22 Jun 23 | Panem Sandra PHD | Non-Employee Stock Option Common Stock | Grant | Acquire A | No | No | 12.99 | 1,200 | 15.59 k | 1,200 |
22 Jun 23 | Burns Thomas M. | Non-Employee Stock Option Common Stock | Grant | Acquire A | No | No | 12.99 | 2,400 | 31.18 k | 2,400 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
11 Apr 24
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
11 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
11 Apr 24
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
11 Apr 24
Press releases
Acorda Therapeutics Announces Delisting from Nasdaq
15 Apr 24
Acorda Therapeutics Announces Nasdaq Delisting Notification
3 Apr 24
Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement
1 Apr 24
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
1 Apr 24